Literature DB >> 35859544

Inherited genetics of adult diffuse glioma and polygenic risk scores-a review.

Jeanette E Eckel-Passow1, Daniel H Lachance2, Paul A Decker1, Thomas M Kollmeyer2, Matthew L Kosel1, Kristen L Drucker2, Susan Slager1, Margaret Wrensch3, W Oliver Tobin4, Robert B Jenkins2.   

Abstract

Knowledge about inherited and acquired genetics of adult diffuse glioma has expanded significantly over the past decade. Genomewide association studies (GWAS) stratified by histologic subtype identified six germline variants that were associated specifically with glioblastoma (GBM) and 12 that were associated with lower grade glioma. A GWAS performed using the 2016 WHO criteria, stratifying patients by IDH mutation and 1p/19q codeletion (as well as TERT promoter mutation), discovered that many of the known variants are associated with specific WHO glioma subtypes. In addition, the GWAS stratified by molecular group identified two additional novel regions: variants in D2HGDH that were associated with tumors that had an IDH mutation and a variant near FAM20C that was associated with tumors that had both IDH mutation and 1p/19q codeletion. The results of these germline associations have been used to calculate polygenic risk scores, from which to estimate relative and absolute risk of overall glioma and risk of specific glioma subtypes. We will review the concept of polygenic risk models and their potential clinical utility, as well as discuss the published adult diffuse glioma polygenic risk models. To date, these prior genetic studies have been done on European populations. Using the published glioma polygenic risk model, we show that the genetic associations published to date do not generalize across genetic ancestries, demonstrating that genetic studies need to be done on more diverse populations.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  genetics; glioma; polygenic; risk; variants

Year:  2022        PMID: 35859544      PMCID: PMC9290891          DOI: 10.1093/nop/npac017

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  58 in total

1.  Differentiation between glioblastoma, brain metastasis and subtypes using radiomics analysis.

Authors:  Moran Artzi; Idan Bressler; Dafna Ben Bashat
Journal:  J Magn Reson Imaging       Date:  2019-01-11       Impact factor: 4.813

2.  Genomics is failing on diversity.

Authors:  Alice B Popejoy; Stephanie M Fullerton
Journal:  Nature       Date:  2016-10-13       Impact factor: 49.962

3.  A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Authors:  Simon N Stacey; Patrick Sulem; Aslaug Jonasdottir; Gisli Masson; Julius Gudmundsson; Daniel F Gudbjartsson; Olafur T Magnusson; Sigurjon A Gudjonsson; Bardur Sigurgeirsson; Kristin Thorisdottir; Rafn Ragnarsson; Kristrun R Benediktsdottir; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Cristina Corredera; Victoria Fuentelsaz; Pilar Grasa; Sebastian Navarrete; Fernando Fuertes; Maria D García-Prats; Enrique Sanambrosio; Angeles Panadero; Ana De Juan; Almudena Garcia; Fernando Rivera; Dolores Planelles; Virtudes Soriano; Celia Requena; Katja K Aben; Michelle M van Rossum; Ruben G H M Cremers; Inge M van Oort; Dick-Johan van Spronsen; Jack A Schalken; Wilbert H M Peters; Brian T Helfand; Jenny L Donovan; Freddie C Hamdy; Daniel Badescu; Ovidiu Codreanu; Mariana Jinga; Irma E Csiki; Vali Constantinescu; Paula Badea; Ioan N Mates; Daniela E Dinu; Adrian Constantin; Dana Mates; Sjofn Kristjansdottir; Bjarni A Agnarsson; Eirikur Jonsson; Rosa B Barkardottir; Gudmundur V Einarsson; Fridbjorn Sigurdsson; Pall H Moller; Tryggvi Stefansson; Trausti Valdimarsson; Oskar T Johannsson; Helgi Sigurdsson; Thorvaldur Jonsson; Jon G Jonasson; Laufey Tryggvadottir; Terri Rice; Helen M Hansen; Yuanyuan Xiao; Daniel H Lachance; Brian Patrick O Neill; Matthew L Kosel; Paul A Decker; Gudmar Thorleifsson; Hrefna Johannsdottir; Hafdis T Helgadottir; Asgeir Sigurdsson; Valgerdur Steinthorsdottir; Annika Lindblom; Robert S Sandler; Temitope O Keku; Karina Banasik; Torben Jørgensen; Daniel R Witte; Torben Hansen; Oluf Pedersen; Viorel Jinga; David E Neal; William J Catalona; Margaret Wrensch; John Wiencke; Robert B Jenkins; Eduardo Nagore; Ulla Vogel; Lambertus A Kiemeney; Rajiv Kumar; José I Mayordomo; Jon H Olafsson; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2011-09-25       Impact factor: 38.330

4.  T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.

Authors:  Sohil H Patel; Laila M Poisson; Daniel J Brat; Yueren Zhou; Lee Cooper; Matija Snuderl; Cheddhi Thomas; Ana M Franceschi; Brent Griffith; Adam E Flanders; John G Golfinos; Andrew S Chi; Rajan Jain
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

5.  Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation.

Authors:  Daesung Kang; Ji Eun Park; Young-Hoon Kim; Jeong Hoon Kim; Joo Young Oh; Jungyoun Kim; Yikyung Kim; Sung Tae Kim; Ho Sung Kim
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

Review 6.  Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.

Authors:  Yiwey Shieh; Martin Eklund; Lisa Madlensky; Sarah D Sawyer; Carlie K Thompson; Allison Stover Fiscalini; Elad Ziv; Laura J Van't Veer; Laura J Esserman; Jeffrey A Tice
Journal:  J Natl Cancer Inst       Date:  2017-01-27       Impact factor: 13.506

7.  Personalized profiles for disease risk must capture all facets of health.

Authors:  Mark McCarthy; Ewan Birney
Journal:  Nature       Date:  2021-09       Impact factor: 49.962

8.  Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.

Authors:  Kyle M Walsh; Veryan Codd; Ivan V Smirnov; Terri Rice; Paul A Decker; Helen M Hansen; Thomas Kollmeyer; Matthew L Kosel; Annette M Molinaro; Lucie S McCoy; Paige M Bracci; Belinda S Cabriga; Melike Pekmezci; Shichun Zheng; Joseph L Wiemels; Alexander R Pico; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Daniel H Lachance; Brian Patrick O'Neill; Hugues Sicotte; Jeanette E Eckel-Passow; Pim van der Harst; John K Wiencke; Nilesh J Samani; Robert B Jenkins; Margaret R Wrensch
Journal:  Nat Genet       Date:  2014-06-08       Impact factor: 38.330

9.  Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Authors:  Tyler M Seibert; Chun Chieh Fan; Yunpeng Wang; Verena Zuber; Roshan Karunamuni; J Kellogg Parsons; Rosalind A Eeles; Douglas F Easton; ZSofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; Kenneth Muir; Henrik Grönberg; Fredrik Wiklund; Markus Aly; Johanna Schleutker; Csilla Sipeky; Teuvo Lj Tammela; Børge G Nordestgaard; Sune F Nielsen; Maren Weischer; Rasmus Bisbjerg; M Andreas Røder; Peter Iversen; Tim J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul Pharoah; Nora Pashayan; Kay-Tee Khaw; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokolorczyk; Wojciech Kluzniak; Lisa Cannon-Albright; Hermann Brenner; Katarina Cuk; Kai-Uwe Saum; Jong Y Park; Thomas A Sellers; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Judith A Clements; Amanda Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Andrzej Kierzek; David S Karow; Ian G Mills; Ole A Andreassen; Anders M Dale
Journal:  BMJ       Date:  2018-01-10

10.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

Authors:  Nora Pashayan; Steve Morris; Fiona J Gilbert; Paul D P Pharoah
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.